Trade These, Not Those: Capital Rotation in Motion as Blade, Kraig, Psyence, and Verb Redefine the Small-Cap Narrative
DENVER, Colo., Aug 04, 2025 (247marketnews.com)- In a market still dominated by rate headlines and ETF-driven flows, the most interesting money is chasing transformation.
Trade These: Joby (NYSE:JOBY) and Blade Air Mobility (NASDAQ:BLDE)
Blade just hit reset in the best way possible, announcing it will sell its entire passenger business to Joby Aviation (NYSE:JOBY) for up to $125 million, transforming the company into Strata Critical Medical, a pure-play, high-margin medical logistics platform.
“This transaction enables the Company to become laser focused on broadening our offerings across the medical logistics and solutions value chain with a singular strategy and significant deployable capital for acquisitions and organic expansion,” said Rob Wiesenthal, CEO.
Why it matters:
- Blade’s medical segment already comprises 84% of Segment Adjusted EBITDA.
- Its Trinity Medical unit is one of the largest organ transporters in the U.S.
- Access to Joby’s eVTOL aircraft ensures cutting-edge logistics scalability.
- With Wiesenthal moving to Joby and veteran leadership staying at Strata, it’s now a focused growth asset with strong fundamentals and acquisition capital.
Trade This: Kraig Biocraft Laboratories (OTCQB:KBLB)
KBLB just executed its most successful production run to date, automating the reeling of over 250kg of spider silk cocoons, a milestone in scaling the world’s strongest biofiber.
“Our team is making continuous refinements to tailor the reeling equipment for spider silk, and we’re already seeing how those adjustments lead to better, more consistent fibers,” said COO Jon Rice.
Why it matters:
- Spider silk has real-world applications in military textiles, medical sutures, and performance apparel.
- KBLB’s automation push reduces labor costs and boosts throughput.
- Paired with recent rearing capacity expansions in Asia, this positions the company to commercialize at scale, potentially making it the first vertically integrated spider silk producer globally.
Trade This: Psyence BioMed (NASDAQ:PBM)
Psyence BioMed is building a regulated clinical model around natural psychedelic therapies, and its latest update shows real traction:
“This change is expected to significantly broaden our eligible patient pool, future patients and increase the trial’s clinical relevance and impact.”
Why it matters:
- A critical protocol amendment now allows non-terminal cancer patients into trials, vastly expanding the addressable market.
- Three clinical sites have been activated, with enrollment imminent.
- The company is backed by a Scientific Advisory Board of global neuroscience leaders and has a firm regulatory handle with HREC approval.
- A pipeline focused on PTSD, substance use disorders, and complex depression gives it long-term upside in a crowded, yet still emerging, therapeutic space.
Trade This: Siyata Mobile (NASDAQ:SYTA)
SYTA’s pending $185 million reverse merger with Core Gaming is being overlooked — and it shouldn’t be.
Why it matters:
- The pivot from rugged mobile hardware to AI-powered content and entertainment delivery is bold.
- SYTA is a tiny float stock with elevated short interest.
- If Nasdaq clears the deal and insiders begin buying, SYTA could reprice rapidly, especially with institutional capital watching for post-close momentum.
Trade This: Verb Technology / TON Strategy (NASDAQ:VERB)
Verb is executing the most aggressive pivot in the public markets: a $558 million PIPE to become the first publicly traded Toncoin ($TON) treasury reserve, rebranding as TON Strategy Co. (TSC).
“Permanent capital vehicles are particularly suitable for long-term holdings of $TON, which not only has the potential to compound in value, but also offers staking yield,” said incoming Executive Chairman Manuel Stotz.
Why it matters:
- $TON is now Telegram’s exclusive blockchain.
- With 87 million U.S. users and 1 billion globally, Telegram is crypto’s most powerful distribution layer.
- TSC will be one of the largest $TON holders worldwide, generating cash-flow-positive staking yield and leveraging crypto-native network effects.
Trade This: Venu (NYSE:VENU)
VENU is consolidating around $14, with short interest high and Cenorium’s $22.30 price target still in play.
Why it matters:
- CEO J.W. Roth personally invested $5 million, with plans to scale to $20 million, into NNN FireSuites.
- These REIT-style, high-yield hospitality units carry 11% projected cap rates, with no property tax, maintenance, or insurance risk.
- The entertainment + real estate hybrid model has $5B in pipeline, and the Reg A overhang is gone, setting up for a technical breakout.
Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.
For additional 247marketnews.com Siyata disclosure https://247marketnews.com/syta-siyata-mobile-update/, or https://247marketnews.com/venu-disclosure/ for additional VENU disclosure, or https://247marketnews.com/kblb-disclosure/ for KBLB disclosure.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com